Access Presentations​

Click on each presentation title to open & download a PDF of the slides.

Day One

Chair: Luis Raez, MD (Memorial Cancer Institute)

State of the Art for Stage III Unresectable NSCLC
Jhanelle Gray, MD (Moffitt Cancer Center)

When to Use PD(L)1 Monotherapy for Advanced NSCLC
Shirish Gadgeel, MD (Henry Ford Health)

Chemotherapy + PD(L)1 Combinations in Advanced NSCLC
Ticiana Leal, MD (Emory Winship Cancer Institute)

Integrating Dual Checkpoint Inhibition in Advanced NSCLC
Hossein Borghaei, DO (Fox Chase Cancer Center)

Combining ADCs and Immunotherapy in NSCLC
Alissa Cooper, MD (Memorial Sloan Kettering Cancer Center)

Case Study: Immunotherapy in Advanced Lung Cancer I
Kartik Konduri, MD (Texas Oncology)

Chair: Davey Daniel, MD (OneOncology)

The New Frontier in Limited-Stage SCLC
Quynh-Nhu Nguyen, MD (MD Anderson Cancer Center)

Optimizing Frontline Therapy for Extensive-Stage SCLC
Lauren Byers, MD, PhD (MD Anderson Cancer Center)

Reimagining Relapsed SCLC
Misty Shields, MD, PhD (Indiana University)

SCLC Biomarkers: Ready for Prime Time?
Carl Gay, MD, PhD (MD Anderson Cancer Center)

Managing Mesothelioma
Melina Marmarelis, MD, MSCE (University of Pennsylvania)

Searching for New Options for Thymic Malignancies
Chul Kim, MD (Georgetown University)

Case Study: Relapsed SCLC
Jason Porter, MD (West Cancer Center & Research Institute)

Chair: Ibiayi Dagogo-Jack, MD (Massachusetts General Hospital)

The ABCs of NGS in Lung Cancer: Current Standard of Care and Future Prospectives
Christine Lovly, MD, PhD (Vanderbilt University Medical Center)

Frontline EGFR Strategies: TKI +/- Chemotherapy
Rachel Sanborn, MD, (Providence Cancer Institute)

Frontline EGFR Strategies: TKI + Non-chemotherapy Options
Xiuning Le, MD, PhD (MD Anderson Cancer Center)

EGFR Exon 20 and Atypical Mutations
John Heymach, MD, PhD (MD Anderson Cancer Center)

Overcoming EGFR TKI Resistance
Jonathan Riess, MD (UC Davis Health)

New Horizons in HER2 for NSCLC
Mark Socinski, MD (AdventHealth Cancer Institute)

MET in NSCLC: Current and Emerging Options
Paul Paik, MD (Memorial Sloan Kettering Cancer Center)

Case Study: EGFR mutant NSCLC
Janet Tu, MD (MD Anderson Cancer Center)

Chair: R. Steven Paulson, MD (Texas Oncology)

Leveraging Liquid Biopsy in Lung Cancer
Christian Rolfo, MD, PhD (Mount Sinai Health System)

Beyond the Hype: The Hope for AI in Clinical Oncology
Sandip Patel, MD (UC San Diego Health)

TTFields for the Thoracic Oncologist
Joshua Sabari, MD (New York University Langone)

Social Media for the Practicing Oncologist
Narjust Florez, MD (Dana-Farber Cancer Institute)

Evolving Partnership with Patient Advocacy
Terri Conneran (KRAS Kickers)

Healthcare Policy for Today’s Oncologist
Stephen Schleicher, MD, MBA (Tennessee Oncology)

Day Two

Chair: Stephen Liu, MD (Georgetown University)

Optimal Duration of Immunotherapy: Finding the Sweet Spot
Balazs Halmos, MD (Montefiore Einstein Cancer Center )

Rechallenge with Immunotherapy in NSCLC
Wade Iams, MD (Vanderbilt-Ingram Cancer Center)

Harmony of Hope: Confronting Brain Metastases in the Symphony of Lung Cancer
Estelamari Rodriguez, MD, MPH (University of Miami)

Toxicity and Contraindications for Immunotherapy in NSCLC
Sheena Bhalla, MD (UT Southwestern Medical Center)

Immunotherapy & Targeted Therapy in NSCLC: Sequence, Toxicity
Julia Rotow, MD (Dana-Farber Cancer Institute)

Biomarker Selection for Immunotherapy in NSCLC
Ferdinandos Skoulidis, MD, PhD (MD Anderson Cancer Center)

Case Study: Immunotherapy in Advanced Lung Cancer II
Edgardo Santos, MD, FACP (The Oncology Institute of Hope and Innovation)

Chair: Lyudmila Bazhenova, MD (UC San Diego Health)

Best Practices in ALK+ Lung Cancer
Vincent Lam, MD (Johns Hopkins Kimmel Cancer Center)

Rare Fusions in NSCLC: ROS1/RET/NTRK/NRG1
Alexander Drilon, MD (Memorial Sloan Kettering Cancer Center)

Strategies in BRAF+ NSCLC
Marcelo Negrao, MD (MD Anderson Cancer Center)

Current Strategies for KRAS-G12C NSCLC
Melissa Johnson, MD (Sarah Cannon Research Institute)

ADCs in Lung Cancer: A Transformative Therapeutic Class?
Joshua Reuss, MD (Georgetown University)

Case Study: ALK+ NSCLC
Abhirami Vivekanandarajah, MD (New York Cancer & Blood Specialists)

Chair: Tina Cascone, MD, PhD (MD Anderson Cancer Center)

Lung Cancer Screening & Smoking Cessation
Ray Osarogiagbon, MD (Baptist Memorial Health Care)

Targeted Perioperative Therapy for Early-Stage NSCLC
Gregory Riely, MD, PhD (Memorial Sloan Kettering Cancer Center)

Adjuvant Immunotherapy for NSCLC
Jessica Donington, MD, MSCR (University of Chicago Medicine)

Neoadjuvant Immunotherapy for NSCLC
Patrick Forde, MBBCh (Johns Hopkins Kimmel Cancer Center)

Perioperative Immunotherapy for NSCLC
Karen Kelly, MD (International Association for the Study of Lung Cancer)

Case Study: Early Lung Cancer
Eric Nadler, MD, MPP (Texas Oncology)

Chair: Susan Scott, MD (Johns Hopkins Kimmel Cancer Center)

Impact of Adjuvant After Neoadjuvant Therapy
Jamie Chaft, MD (Memorial Sloan Kettering Cancer Center)

Surgical Dogma, Aspirations, and Reality After Neoadjuvant Therapy for NSCLC
Brendon Stiles, MD (Montefiore Einstein Cancer Center)

Selection of Endpoints: Impact on Practice
Julie Brahmer, MD (Johns Hopkins Kimmel Cancer Center)

IDEOlogy's Sound Bites platform offers a convenient, non-promotional way to stay up-to-date through short video clips from distinguished thought leaders.

No app to download. No ads.

Just timely clinical trial updates sent directly to your text messages.

Join the #TexasLung25 invite list